Prostate cancer medicine hailed as a "milestone" breakthrough may not be available to every patient after a revision of the drug guidelines, according to the NHS.
Men in England who have already been treated with a new-generation cancer drug would not be eligible for Enzalutamide, according to the National Institute for Health and Care Excellence (Nice).
Nice, the public body which decides the cost-effectiveness of medicines for NHS patients, said the new drug should not be used by patients who had already taken abiraterone.
Enzalutamide blocks molecular signals driving prostate cancer and improved survival by 30% in men who had not undergone chemotherapy.
A further 80% of men with advanced cancer had the progression delayed, even if the tumour had failed to respond to other treatments.
More top news
The four-month-old baby died after being snatched out of his mother's arms and savaged by the family dog in October.
Liam Payne's outburst came after X Factor judge Louis Walsh criticised a reporter over a question about Payne's girlfriend Cheryl.
Spotting the warning signs for the many private causes of self-harm can be hard in the era of social media. Here's what you can do to help.